Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   4300 (Custom)
AR Bank # 0658 Klebsiella pneumoniae
Study ID: DLX-18

Biosample Accession #: SAMN11953808

   




Panel:  Delafloxacin (DLX)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 4S
Ampicillin >32R
Ampicillin/sulbactam 132R
Aztreonam <=2S
Cefazolin 4I
Cefepime <=0.5S
Cefotaxime <=0.5S
Cefotaxime/clavulanic acid 1<=0.25---
Cefoxitin 8S
Ceftazidime <=1.0S
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone <=1.0S
Chloramphenicol >16R
Ciprofloxacin >8R
Colistin 0.5I
Delafloxacin 22R
Doripenem <=0.12S
Ertapenem <=0.12S
Gentamicin 0.5S
Imipenem <=0.5S
Imipenem+chelators 3<=0.25---
Levofloxacin >8R
Meropenem <=0.12S
Piperacillin/tazobactam 116SDD
Tetracycline 4S
Tigecycline 2<=0.5S
Tobramycin 8R
Trimethoprim/sulfamethoxazole 1>8R
Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
SDD (Susceptible Dose Dependent)
S – I –R Interpretation (INT) derived from CLSI 2025 M100 S35
1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aadA2, aph(3')-Ia, aph(3')-Ib, aph(6)-Id
Beta-lactam OXA-1, SHV-11
Macrolide-Lincosamide-Streptogramin mph(A)
Phenicols/Bicyclomycins catB4
Sulfonamides sul1, sul2
Trimethoprim dfrA12
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
04/11/23INT was updated with a new value for Tobramycin: from 'I' to 'R'
Top of Page
TOP